INO (Inovio Pharmaceuticals Inc) Rentabilitas dodolan miturut bathi reged

INO (Inovio Pharmaceuticals, Inc.) - tandha merek perusahaan

Geopolitical tensions and bio-threats are driving the public sector to invest in antiviral developments, although sanctions complicate raw material logistics. Demand for immunotherapy is rising as DNA medicine undergoes commercialization. GURU.Markets analytics includes this gross income metric, where the -919.40 level captures the current state of production yield for Inovio Pharmaceuticals (INO), whose positions are protected by unique electroporation patents.

Tingkat bathi miturut bathi reged: inovio.com (INO) kanggo 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar Inovio Pharmaceuticals (INO)

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental:Inovio Pharmaceuticals
Sampel barang Inovio Pharma

Gross margin measures the portion of revenue remaining after paying direct production costs, allowing for an assessment of cost management efficiency and the product's pricing power. By analyzing the current gross margin of Inovio Pharmaceuticals (INO), an investor sees a balance between R&D expenditures and financial stability, where cost control during the preparation of DNA vaccines for regulatory approval determines future return on equity.